SCHEMBL29699400

SCHEMBL29699400

FC(F)(F)Oc1ccc(Cl)cc1N1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 1/20 0.48
CACNA2D2 Q9NY47 1/20 0.48
ALDH1A1 P00352 8/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
POLB P06746 2/20 0.44
MAPK1 P28482 3/20 0.43
CHKA P35790 1/20 0.42
MGLL Q99685 2/20 0.42
ABHD6 Q9BV23 2/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MCOLN3 Q8TDD5 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22815951 0.82 HTR3E (0.43) CACNA2D1CACNA2D2ALDH1A1HTR3EHTR3B
SCHEMBL2968786 0.81 ALDH1A1 (0.50) CACNA2D1CACNA2D2ALDH1A1LMNAKDM4E
SCHEMBL2979005 0.79 ALDH1A1 (0.47) CACNA2D1CACNA2D2ALDH1A1LMNAKDM4E
SCHEMBL29699492 0.75 MRGPRX4 (0.44) ALDH1A1LMNAHTTMAPK1MEN1
SCHEMBL22668889 0.75 MAPT (0.54) LMNAKDM4EHTR3EHTR3BHTR3A
SCHEMBL28849647 0.73 MRGPRX4 (0.44) ALDH1A1LMNAHTTMAPK1MEN1
SCHEMBL29699554 0.72 FFAR4 (0.56) ALDH1A1KDM4EPOLBMAPK1MEN1
SCHEMBL28570167 0.71 ALDH1A1 (0.53) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL9830614 0.70 ALDH1A1 (0.65) ALDH1A1LMNAKDM4EHTTPOLB
SCHEMBL9240089 0.70 NR1I2 (0.47) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CACNA2D1 2604/4885CACNA2D2 2937/4885ALDH1A1 481/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CACNA2D1 3085/4885CACNA2D2 3358/4885ALDH1A1 552/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT CACNA2D1 2604/4885CACNA2D2 2937/4885ALDH1A1 481/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CACNA2D1 2604/4885CACNA2D2 2937/4885ALDH1A1 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.